How Artificial General Intelligence Could Transform Disease Treatment

Artificial general intelligence (AGI) may enable human‑level reasoning and critical thinking across multiple cognitive domains. In recent months, AI developers have claimed that AGI will soon be capable of solving all disease. AGI generally refers to AI systems that can perform human‑level reasoning and critical thinking across various cognitive domains—a goal many researchers pursue eagerly. One core idea is that once AGI is achieved, the most demanding cognitive tasks could be offloaded to AI systems to discover solutions. This is because successful AGI systems would likely be able to condense centuries of human experience and scientific discovery into readily usable data points, generating unprecedented productive output. Another premise is that the raw ingredients for curing many, if not all, diseases already exist; the challenge lies in finding the right permutations, combinations, and scope of scientific application to use them effectively.

Consider the traditional drug discovery process, which typically involves isolating genes or proteins, identifying vulnerabilities, and then designing defensive structures or molecules that can counteract harmful elements. This process entails considerable trial and error, akin to searching for a specific key among billions to fit a particular protein folding pattern. However, AI systems can process data sets far beyond human capacity, uncovering interactions between proteins and molecular structures that were previously unimaginable. A landmark article in the Journal of Pharmaceutical Analysis by Fu et al. highlights how AI accelerates and structures what was once considered “luck” in drug discovery: “drug discovery has historically relied heavily on serendipity, with many significant breakthroughs occurring through chance observations or unintended findings. However, AI offers the potential to remove much of the uncertainty in this process, dramatically improving the chances of identifying commercially viable drug candidates while reducing both costs and time.” The authors emphasize that machine learning’s ability to map previously unknown relationships and predict combinations aligned with biological complexity cannot be underestimated.

Another study published in Drug, Design, Development and Therapy found that AI‑enabled drug discovery lowered costs and shortened the drug development lifecycle by improving efficiency in patient recruitment, data analysis, and clinical trial design. This is especially relevant because drug pricing is heavily influenced by the resource‑intensive nature of drug design and discovery; pharmaceutical companies often invest billions of dollars and many years to bring a single formulation to market. If AI can trim some of these expenses, there may be an opportunity to pass savings on to consumers.

Of course, reaching the point where AGI can help cure disease at scale is not straightforward. Significant challenges remain. As noted in Machine Learning for Brain Disorders, clinical trials inherently involve human lives, and even if AGI speeds up development, trials still require human time and oversight. In fact, AI‑driven trials might take longer due to heightened scrutiny regarding human impact. Moreover, AGI systems are only as good as the data they receive; human knowledge is currently fragmented across disparate sources. While AI can serve as a unifying factor, it still needs proper access and guidance to leverage that information effectively. Finally, cohesive policy efforts are essential. Although AGI offers substantial benefits, establishing guardrails and unified policies is crucial as we navigate this new, uncharted territory.

Source link